Literature DB >> 16579838

Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection.

Taiji Akamatsu1, Taro Mochizuki, Yoko Okiyama, Akihiro Matsumoto, Hideharu Miyabayashi, Hiroyoshi Ota.   

Abstract

BACKGROUND: The clinical features and clinical course of Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue (MALT) lymphoma are unclear and a treatment strategy has not yet been established. AIM: To clarify the clinical differences between H. pylori-positive and H. pylori-negative gastric MALT lymphoma, we compared these two types of gastric MALT lymphoma.
MATERIALS AND METHODS: Fifty-seven patients with localized gastric MALT lymphoma were studied. H. pylori infection was present in 41 and absent in 16. Treatment consisted of antibiotic therapy and/or 30 Gy radiation therapy. Response assessment was performed every 3-6 months by esophagogastroduodenoscopy including gathering biopsy samples, endoscopic ultrasonography, clinical examination, and various imaging procedures. The median follow-up period was 37 months.
RESULTS: There were no significant differences between H. pylori-positive and H. pylori-negative gastric MALT lymphoma patients in terms of sex, age, stage, gross phenotype, affected area of the stomach, or the presence of monoclonality. Complete regression was achieved with antibiotic therapy against H. pylori-negative gastric MALT lymphoma in one of nine patients (11.1%), compared to 28 of 38 patients (73.7%) with H. pylori-positive gastric MALT lymphoma (p < .001). Radiation therapy showed high effectiveness for the local control of H. pylori-negative or antibiotic-resistant gastric MALT lymphoma (92.9%), although distant recurrence was recognized in three of 14 patients (21.4%). Two of 16 patients (12.5%) with H. pylori-negative gastric MALT lymphoma died because of the transformation of the disease into diffuse large B-cell lymphoma. There was a significant difference in both the overall and cause-specific survival rate between the two groups (p = .038).
CONCLUSION: Radiation therapy is the effective treatment for H. pylori-negative or antibiotic-resistant localized gastric MALT lymphoma. However, careful systemic follow-up for distant involvement should be required. Transformation into diffuse large B-cell lymphoma is thought to be the important cause of death in patients with gastric MALT lymphoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16579838     DOI: 10.1111/j.1523-5378.2006.00382.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  12 in total

Review 1.  Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review.

Authors:  Naoki Asano; Katsunori Iijima; Tomoyuki Koike; Akira Imatani; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

2.  Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma.

Authors:  Hyung Soon Park; Yu Jin Kim; Woo Ick Yang; Chang Ok Suh; Yong Chan Lee
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

Review 3.  Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.

Authors:  Sabarish Ayyappan; Basem M William
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

4.  Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Sang-Won Kim; Do Hoon Lim; Yong Chan Ahn; Won Seog Kim; Seok Jin Kim; Young Hyeh Ko; Kyoung-Mee Kim
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

5.  Two Cases of Diffuse Large B-Cell Lymphomas in the Cervical Lymph Nodes in Patients with Low-Grade Gastric Marginal Zone B-Cell Lymphoma (MALT Lymphoma).

Authors:  Ji Hoon Jung; Hwoon-Yong Jung; Hwan Yoon; Jae Kwang Lee; Ji Hoon Kang; Sung Jin Jeon; Young-Su Park; Jin-Ho Kim
Journal:  Clin Endosc       Date:  2013-05-31

Review 6.  Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Andriani; Francesca Cristofari; Chiara Bassanelli; Gian Paolo Spinelli; Silverio Tomao; Sergio Morini
Journal:  Med Oncol       Date:  2009-03-24       Impact factor: 3.064

7.  Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years.

Authors:  Yu Ohkubo; Yoshihiro Saito; Hiroki Ushijima; Masahiro Onishi; Tomoko Kazumoto; Jun-Ichi Saitoh; Nobuko Kubota; Hirofumi Kobayashi; Nobuo Maseki; Yu Nishimura; Masafumi Kurosumi
Journal:  J Radiat Res       Date:  2017-07-01       Impact factor: 2.724

8.  Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication.

Authors:  Yoshimasa Saito; Hidekazu Suzuki; Hitoshi Tsugawa; Hiroyuki Imaeda; Juntaro Matsuzaki; Kenro Hirata; Naoki Hosoe; Masahiko Nakamura; Makio Mukai; Hidetsugu Saito; Toshifumi Hibi
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

9.  Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma according to Helicobacter pylori infection status: a single-center experience.

Authors:  Kwang Duck Ryu; Gwang Ha Kim; Seong Oh Park; Kwang Jae Lee; Jung Youn Moon; Hye Kyung Jeon; Dong Hoon Baek; Bong Eun Lee; Geun Am Song
Journal:  Gut Liver       Date:  2013-12-24       Impact factor: 4.519

10.  Clinical Outcome of Eradication Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to H. pylori Infection Status.

Authors:  Ju Seok Kim; Sun Hyung Kang; Hee Seok Moon; Jae Kyu Sung; Hyun Yong Jeong
Journal:  Gastroenterol Res Pract       Date:  2016-02-29       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.